/   Home   /   Newsroom   /   Research News

Targeting Mitogen-activated Protein Kinase Signaling in Ras Homolog Enriched in Brain Drives Human Cancer

Jul 22, 2016     Email"> PrintText Size

PI3K/TSC/mTOR pathway plays a crucial role in multiple cellular behaviors, including cell survival, metabolism, proliferation, and autophagy and so on. Aberrant activation of this pathway is associated with protein translation, which is required for cell proliferation and survival in many types of cancers. The efforts of cancer genome sequencing have identified recurrent activating mutations of Rheb. It is a key molecular in PI3K/AKT/mTOR pathway in kidney and endometrial carcinoma. However, the role of this mutation in pathogenesis of these human cancers is still not well understood.

Disease Genomics Group from Dalian Institute of Chemical Physics (DICP), led by Dr. LIU Yang, demonstrated a novel molecular mechanism of tumorigenesis in renal and endometrium carcinoma with activating mutation of Ras homolog enriched in brain (Rheb). The research provides a potential therapeutic strategy for Rheb-driven human cancers.

Dr. LIU's team showed that Rheb-Y35N mutation can not only lead to constitute “mammalian target of rapamycin complex 1” (mTORC1) activation, but sustained mitogen-activated protein kinase (MAPK) activation. In addition, inhibition of both mTOR and MAPK pathway could significantly suppress Y35N-driven tumor growth in vitro and in vivo.

Furthermore, by collaborating with Dr. LI Guohui's research group, they found that Rheb can directly bind to the kinase domain of 5'AMP-activated protein kinase (AMPKα1) to regulate its activity. In contrast the Y35N mutant impairs AMPK activation by competitively binding to AMPKα, it can lead to attenuated pBRAF-S729. Consequently, the inhibitory site of BRAF activity subsequently sustained MEK-ERK activation.

 

Proposed model for the interaction of Rheb with AMPK and regulation for MAPK pathway (Image by LIU Yang)

This study provided a novel insight into the cellular mechanism of Rheb-Y35N-driven tumor. It suggested a potential therapeutic approach and clinical basis to treat the tumor with Rheb-Y35N mutation. These results were published on Oncogene journal.

Attachment:

(Editor: CHEN Na)

Contact

LU Xinyi

Dalian Institute of Chemical Physics

Phone: 86-411-84379201
E-mail: luxinyi@dicp.ac.cn

Related Articles

cancer;medical imaging;ultrasound;breast cancer;mammogram;breast screening;breast cancer screening

China Enlists AI to Diagnose Breast Cancer

Jul 10, 2017

Doctors in China will soon read patient breast scans with the help of machines. The National Clinical Research Center for Cancer (NCRCC) said Friday that it has signed a deal with the Institute of Computing Technology under the Chinese Academy of Sciences (CAS) to use art...

cancer;diagnosis;nanoplatform;dual-mode MR imaging; drug delivery system;cisplatin; pH-responsive;cancer chemotherapy

A Nanoplatform to Benefit Clinical Diagnosis and Chemotherapy of Cancer

Jul 04, 2017

Collaborating with researchers from Anhui Medical University and Shanghai Jiao Tong University, a study team led by Professor WU Zhengyan in Institute of Technical Biology and Agriculture Engineering, Hefei Institutes of Physical Science, developed a nanoplatform for targ...

Contact Us

Copyright © 2002 - 2017 Chinese Academy of Sciences